Neuronetics (STIM) EVP receives 33,750 performance-based common shares

Rhea-AI Filing Summary

Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MACAN WILLIAM ANDREW

Role EVP, CLO and CS

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	33,750	$0.00	--

Holdings After Transaction: Common Stock — 913,275 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACAN WILLIAM ANDREW

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO and CS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		A		33,750	A	$0(1)	913,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Common stock received for no consideration upon the satisfaction of performance criteria underlying an award of performance based restricted stock units.

	/s/ Patrick Devine, as Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neuronetics (STIM) report for William Andrew Macan?

Neuronetics reported that EVP, CLO and CS William Andrew Macan received 33,750 shares of common stock. The shares were granted for no cash consideration after performance criteria on performance-based restricted stock units were met, increasing his directly held position to 913,275 shares.

Was the Neuronetics (STIM) insider transaction an open-market buy or a compensation grant?

The transaction was a compensation-related grant, not an open-market purchase. William Andrew Macan received 33,750 common shares for no consideration upon satisfaction of performance criteria on performance-based restricted stock units, reflecting equity compensation rather than a cash-funded share acquisition.

How many Neuronetics (STIM) shares does William Andrew Macan hold after this Form 4?

After the reported grant, William Andrew Macan directly holds 913,275 shares of Neuronetics common stock. This total includes the 33,750 shares he received for no consideration upon meeting performance criteria attached to performance-based restricted stock unit awards.

What triggered the 33,750-share award reported in Neuronetics (STIM) Form 4?

The 33,750-share award was triggered when performance criteria tied to performance-based restricted stock units were satisfied. Upon meeting those targets, William Andrew Macan received common stock for no cash consideration as part of his equity compensation package.

Does the Neuronetics (STIM) Form 4 indicate any insider selling activity?

The Form 4 shows only an acquisition of shares, not a sale. William Andrew Macan received 33,750 common shares for no consideration when performance-based restricted stock units vested, bringing his directly held total to 913,275 shares with no dispositions reported.